RSP vs XBI
Invesco S&P 500 Equal Weight ETF vs SPDR S&P Biotech ETF
- • RSP has the lower expense ratio at 0.20% vs 0.35% for XBI.
- • RSP pays a higher dividend yield (1.51%).
Side-by-side metrics
| Metric | RSP | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.20% | 0.35% |
Dividend yield Trailing 12-month yield. | 1.51% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $93.66B | $10.73B |
YTD return | 11.67% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.85 | 1.10 |
P/E ratio | 22.17 | — |
Last price | $214.01 | $164.01 |
Inception | — | — |
Issuer | Invesco | State Street |
RSP top holdings
| MRNA | Moderna Inc | 0.29% |
| GLW | Corning Inc | 0.29% |
| AMAT | Applied Materials Inc | 0.28% |
| KLAC | KLA Corp | 0.27% |
| TER | Teradyne Inc | 0.27% |
| SNDK | SanDisk Corp Ordinary Shares | 0.27% |
| GEV | GE Vernova Inc | 0.26% |
| LRCX | Lam Research Corp | 0.26% |
| TECH | Bio-Techne Corp | 0.26% |
| UAL | United Airlines Holdings Inc | 0.26% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About RSP
RSP (Invesco S&P 500 Equal Weight ETF) is S&P 500 with each stock equally weighted. Managed by Invesco, the fund carries $93.7B in assets under management, an expense ratio of 0.20%, a dividend yield of 1.51%. Its largest holding is Moderna Inc (MRNA), which represents 0.3% of the portfolio. Real Estate is the fund's largest sector exposure at 5.9%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.